Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

Purpose: To compare the performance of the standard lag time model (LAG model) with the performance of an analytical solution of the transit compartment model (TRANSIT model) in the evaluation of four pharmacokinetic studies with four different compounds. Methods: The population pharmacokinetic analyses were performed using NONMEM on concentration–time data of glibenclamide, furosemide, amiloride, and moxonidine. In the TRANSIT model, the optimal number of transit compartments was estimated from the data. This was based on an analytical solution for the change in drug concentration arising from a series of transit compartments with the same first-order transfer rate between each compartment. Goodness-of-fit was assessed by the decrease in objective function value (OFV) and by inspection of diagnostic graphs. Results: With the TRANSIT model, the OFV was significantly lower and the goodness-of-fit was markedly improved in the absorption phase compared with the LAG model for all drugs. The parameter estimates related to the absorption differed between the two models while the estimates of the pharmacokinetic disposition parameters were similar. Conclusion: Based on these results, the TRANSIT model is an attractive alternative for modeling drug absorption delay, especially when a LAG model poorly describes the drug absorption phase or is numerically unstable.

[1]  P. Marquet,et al.  Population Pharmacokinetic Modeling of Oral Cyclosporin Using NONMEM: Comparison of Absorption Pharmacokinetic Models and Design of a Bayesian Estimator , 2004, Therapeutic drug monitoring.

[2]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[3]  A. Melander,et al.  Comparison of the kinetics of glyburide and its active metabolites in humans , 1995, Journal of clinical pharmacy and therapeutics.

[4]  A. Melander,et al.  Hypoglycemic Activity of Glyburide (Glibenclamide) Metabolites in Humans , 1994, Diabetes Care.

[5]  M O Karlsson,et al.  Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. , 1997, British journal of clinical pharmacology.

[6]  L. Block,et al.  The Impact of Lag Time on the Estimation of Pharmacokinetic Parameters. I. One-Compartment Open Model , 1993, Pharmaceutical Research.

[7]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[8]  Lewis B. Sheiner Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals , 2005, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  R. Savic,et al.  Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults , 2006, Journal of clinical pharmacology.

[10]  E. Niclas Jonsson,et al.  Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257] , 2005, Comput. Methods Programs Biomed..

[11]  J. Wade,et al.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[12]  Mats O. Karlsson,et al.  Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[14]  M. Karlsson,et al.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[15]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[16]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[17]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.